miR-21 is a microRNA (miRNA) frequently overexpressed in human cancers. Here we show that miR-21 is upregulated both in vitro and in vivo by oncogenic Ras, thus linking this miRNA to one of the most frequently activated oncogenes in human cancers. Ras regulation of miR-21 occurs with a delayed kinetic and requires at least two Ras downstream pathways. A screen of human thyroid cancers and non-small-cell lung cancers for the expression of miR-21 reveals that it is overexpressed mainly in anaplastic thyroid carcinomas, the most aggressive form of thyroid cancer, whereas in lung its overexpression appears to be inversely correlated with tumor progression. We also show that a LNA directed against miR-21 slows down tumor growth in mice. Consistently, a search for mRNAs downregulated by miR-21 shows an enrichment for mRNAs encoding cell cycle checkpoints regulators, suggesting an important role for miR-21 in oncogenic Ras-induced cell proliferation.
Introduction
The involvement of microRNAs (miRNAs) in cancer emerged from several reports showing that they are aberrantly expressed in neoplastic tissues (Lu et al., 2005; Volinia et al., 2006) The identification of several targets of miRNAs involved in cancer has led to the widely accepted idea that networks comprising classical oncogenes or tumor suppressors and miRNAs have pivotal roles in cancer initiation, progression and metastatization (Esquela-Kerscher and Slack, 2006; Zhang et al., 2007) . Deregulation of miRNAs expression in cancer can occur by genetic mechanisms including amplification, deletion and mutation, as well as by epigenetic silencing (Calin et al., 2004; Zhang et al., 2006) . Moreover, it has recently been demonstrated that oncogenes and tumor suppressors exert their action also by regulating the expression of specific miRNAs. Oncogenic activation of Myc is able to induce the transcription of the oncogenic miRNA cluster miR-17-92, even though its genome-wide effect is a widespread repression of miRNA expression contributing to the tumorigenic potential of lymphoma cells (O 'Donnell, 2005; He et al., 2007; Chang et al., 2008) . Also, miR-34 family miRNAs are direct transcriptional targets of p53, and act in concert with other p53 effectors to downregulate a set of genes involved in cell cycle progression (O 'Donnell, 2005; He et al., 2007) . One of the oncogenes most frequently activated in human cancers is Ras, which, because of its central role in the transduction of extracellular signals, is able to re-programme the transcriptome of cells when constitutively activated. We have recently demonstrated that Ras is able to induce aberrant expression of miRNAs during the transformation of thyroid epithelial cells (Landgraf et al., 2007) . The top-scored upregulated miRNA is miR-21, a miRNA found overexpressed in several solid and hematopoietic malignancies (Krichevsky and Gabriely, 2009) . In vitro studies have demonstrated that miR-21 knockdown in tumor cell lines leads to increased apoptotic cell death (Seike et al., 2009) . Furthermore, miR-21 depletion reduces the growth of tumor cell lines xenografts in mice (Si et al., 2007) . Several target mRNAs have already been validated for miR-21, among which there are at least four known tumor suppressors (PTEN, TPM1, PDCD4 and maspin) and the transcription factor NFIB. The genomic locus encoding miR-21 is not amplified in most cancers, including those expressing very high levels of miR-21, such as glioblastoma and chronic lymphocytic leukemia, suggesting that the deregulated expression of this miRNA occurs at either the transcriptional or the post-transcriptional level or both. The transcription of miR-21 primary RNA is controlled by a conserved upstream enhancer, which has been demonstrated to be regulated by gp130-activated Stat3 in myeloma cells, and by AP-1 in promyelocitic differentiation induced by TPA (Lo¨ffler et al., 2007; Fujita et al., 2008) . We have recently demonstrated that AP-1 activity is necessary, but not sufficient, for the induction of miR-21 triggered by Ras (Talotta et al., 2009) . In this paper we show that the induction of miR-21 by Ras is mediated by at least two different downstream pathways, the Raf-MAPK (mitogen-activated protein kinase) and the phosphatidylinositol 3-kinase (PI3K) pathways. We also show that among human thyroid tumors, miR-21 overexpression is higher in those with anaplastic histotype, and that miR-21 knockdown is able to repress the growth of thyroid tumors xenografts in mice. Importantly, here we show that experimental lung tumors induced in mice by oncogenic Ras activation present overexpression of miR-21, revealing for the first time a link between an oncogene involved in a large fraction of human malignancies and the deregulation of a relevant miRNA in vivo. Screening of 48 cases of non-small-cell lung cancers revealed a correlation between miR-21 level of expression and early stages of such tumor, supporting the hypothesis that miR-21 overexpression can contribute to the early steps of lung cancer development. Finally, we performed a genome-wide screening for miR-21 targets regulated at the mRNA level, showing that the reprogramming of cells by miR-21 overexpression deregulates a network of genes involved in the response to DNA damage and cell cycle checkpoints.
Results

Induction of miR-21 is an early event in Ras-induced neoplastic transformation
We previously detected a strong increase in miR-21 expression upon 2 and 7 days of Ras-oncogene activation (Landgraf et al., 2007) in an inducible system in which a chimeric form of Ras oncoprotein, ER-Ras can be activated by tamoxifen . To rule out the possibility that such induction could be due to tamoxifen treatment, we treated both ER-Ras FRTL-5 and parental FRTL-5 cells with tamoxifen for 2 and 7 days, and measured mature miR-21 expression by both Q-RT-PCR and northern blot (Figure 1a) , showing that miR-21 is strongly induced in thyroid cells only in the presence of oncogenic-Ras activity. We thus, performed a time course of miR-21 induction showing that miR-21 levels start to increase significantly after 12 h of Ras activation (Figure 1b) . To investigate if miR-21 deregulation could be also associated with chronic thyroid cell transformation, we measured miR-21 levels in several independent FRTL-5 cell clones constitutively expressing the human H-RasV12 oncogene . miR-21 expression was analyzed by Q-RT-PCR in seven independent clones of FRTL-5 cells constitutively expressing increasing amounts of H-RasV12 (V30, V35, V21, V12, V29, V39, V27, ordered by increasing oncogene expression), in two empty vector-transfected clones and in parental FRTL-5 cells (Figure 1c ). These data show that miR-21 is persistently overexpressed in Ras-transformed cells. Interestingly, miR-21 is specifically overexpressed only in clones with high expression of oncogenic Ras, that we previously demonstrated to be the less differentiated ones, whereas clones expressing low levels of Ras, maintaining the expression of differentiation markers, show miR-21 expression similar to the controls. Furthermore, as these cells are transformed by the native human Ras oncogene, this finding rules out the possibility that the induction of miR-21 could be an artefact of the chimeric Ras oncoprotein.
Regulation of miR-21 is cell-type specific We asked if Ras is able to induce miR-21 expression in non-epithelial cells. To this purpose we generated Rasinducible NIH 3T3 mouse fibroblasts and tested the induction of miR-21 by Ras in NIH 3T3 cells compared with FRTL-5 cells. The basal level of expression of miR-21 is 20-fold higher in NIH 3T3 cells with respect to FRTL-5 cells, and the activation of Ras induced a transient 30% increase of miR-21 expression in NIH 3T3 cells at 24 h of treatment, by reverting to basal levels at 72 h (Figure 1d ). Compared with NIH 3T3 cells, the kinetics of induction of miR-21 expression by Ras in FRTL-5 cells is slower, but the expression of such miRNA is sustained even 72 h after Ras induction, with miR-21 expression being 50% higher in FRTL-5 with respect to NIH3T3 cells at this time (Figures 1b and d) . We analyzed the ability of Ras in inducing two wellestablished effector pathways, the Raf/MAPK and the ERK and Akt phosphorylation in the two cell lines, we observed that at either times, phospho-ERK was higher in NIH 3T3 with respect to FRTL-5 cells, whereas Akt phosphorylation was higher in FRTL-5 with respect to NIH3T3, despite a lower level of total Akt expression in FRTL-5 ( Figure 1d ). In NIH 3T3 cells the ability of ERRas in inducing focus formation only in the presence of tamoxifen was revealed by focus assay, thus confirming the inducible transforming ability of ER-Ras oncogene in such cell setting ( Figure 1e ).
Activation of different Ras effectors is necessary for miR-21 induction
We then aimed at identifying pathway(s) used by oncogenic Ras to achieve miR-21 induction. To this purpose, we took advantage of the already described Ras effector-domain mutants, each bearing, in addition to the oncogenic mutation V12, a second point mutation in the effector-binding domain enabling the binding of a single effector. Three effector-domain mutants were used: S35, activating the Raf/MAPK pathway; C40, activating PI3K; G37, activating RalGDS. We generated inducible forms for each Ras effector-domain mutant. Clones expressing chimeric oncogenic Ras and its mutants were stimulated with tamoxifen and miR-21 expression was measured by Q-RT-PCR. Figure 2a shows that none of the effector-domain mutants is able to reproduce the induction of miR-21 by Ras despite similar levels of expression of the chimeric constructs. The ability of chimeric Ras effector mutants 
Figure 2 Different pathways contribute to miR-21 induction by Ras. (a) FRTL-5 cell lines stably expressing tamoxifen-inducible forms of Ras chimeras, ER-Ras bearing the oncogenic V12 mutation and three double mutants, each bearing in addition to the V12, one of the effector-specific mutations (S35 for Raf, C40 for PI3K and G37 for RalGDS), were treated with tamoxifen for 24 h or left untreated, then miR-21 was measured by Q-RT-PCR and the expression of Ras chimeras was measured by western blot. b-Actin is used as a loading control. (b) Cells treated as described for panel A were analyzed by western blot. Upper panel: the ability of the Ras chimeras to bind Raf was measured by Raf1-RBD pulldown (see Supplementary Methods) followed by western blot with anti-Ras antibody. Middle panel: ER-Ras expression in the total lysate revealed by anti-Ras antibody, b-actin is used as loading control. Lower panel: phospho AKT and total AKT were measured by specific antibodies, with GAPDH used as loading control. (c) ER-Ras FRTL-5 cells were treated with tamoxifen in the presence of the indicated kinase inhibitors (PD98059 and UO126 for MEK, LY294002 and wortmannin for PI3K, SB202190 and SB203580 for p38MAPK, U-73122 for PLC and Bisindolylmaleimide for PKC, see also Supplementary Methods) for 24 h, then miR-21 was measured by Q-RT-PCR. (d) FRTL-5 cells were transfected with a reporter plasmid in which the firefly luciferase gene is under the control of the miR-21 enhancer (pGL3 miR21-enh) or the empty vector, together with either the human HRas oncogene (V12) or its effector mutants (S35, C40, G37), alone or in combination, as indicated. 48 h after transfection cells were collected and luciferase activities were determined as described in Supplementary Methods.
Regulation of miR-21 by Ras and its role in cancer
D Frezzetti et al in activating the appropriate pathways has been verified by pulldown of active Ras with the Raf1-Ras binding domain as bait, and by checking the phosphorylation of Akt as a marker of PI3K activation. In Figure 2b it is shown that the S35 mutant is able to bind efficiently Raf, although being unable to induce Akt phosphorylation, and conversely, the C40 mutant is able to induce Akt phosphorylation but binding to Raf1 is almost undetectable. A very weak activation of both pathways is obtained by the G37 mutant (Figure 2b ). Such data suggest that miR-21 induction by Ras is achieved through the synergistic action of more than one effector, and, hence, no single pathway is sufficient per se to induce miR-21 expression. We also investigated, among Ras-activated pathways, which one is necessary for the induction of miR-21 through the use of kinase inhibitors. As shown in Figure 2c the induction of miR-21 is completely inhibited by both MEK and PI3K inhibitors. Conversely, inhibition of other Ras effectors such as PLC and PKC, or the unrelated p38 kinase, does not interfere with the induction of miR-21. We then asked if the PI3K and the MAPK pathways, activated in combination, could reproduce the induction of miR-21 by Ras. To answer this question, we measured the ability of Ras effectors mutants, alone or in combination, in inducing the identified Ras-responsive enhancer (Talotta et al., 2009) , demonstrating that the simultaneous activation of MAPK and PI3K pathways does not reproduce the Ras-induced activation (Figure 2d ). Taken together, these results demonstrate that both Raf/MAPK and PI3K pathways are necessary, but not sufficient for miR-21 induction by oncogenic Ras.
Oncogenic Ras induces miR-21 expression in vivo
We reasoned that activation of Ras could be the trigger of miR-21 expression in neoplastic transformation in vivo. To address this point we used a mouse model in which a KRas oncogene is expressed from KRas locus upon CRE-mediated recombination (Guerra et al., 2003) . In such a model it has been shown that the widespread expression of an oncogenic form of KRas is able to induce tumor formation specifically in lung. We thus, measured the expression of miR-21 by RT-PCR in normal lung, lung adenomas and lung adenocarcinomas obtained from KRas V12 -expressing mice. Figure 3 shows that miR-21 expression values in normal lungs and in adenomas are distributed within a small interval of values whereas the carcinomas show a much wider range of variability among samples, comprising samples with miR-21 expression similar to the normal tissues/adenomas, and samples with very high expression of such miRNA. These results reveal a trend of miR-21 overexpression in lung cancer induced in vivo by Ras.
Mir-21 overexpression in human non-small-cell lung cancer correlates with tumor stage The data obtained in mice prompted us to explore in human non-small-cell lung carcinomas the expression of miR-21. We analyzed miR-21 expression in 48 pairs of lung carcinomas and their adjacent noncancerous lung tissues. Clinical features of selected patients are reported in Supplementary Table S3 . We observed an overall trend of overexpression in tumors with respect to the normal samples, as it is represented in Figure 4a Figure 4b . In 26/48 sample pairs miR-21 is expressed in tumors at least twofold with respect to the normal tissue. Of the remaining 22 pairs, in 9/48 miR-21 are weakly overexpressed in tumors (between one and twofold the expression of the normal tissue) and in 13/48 is lower in the tumor with respect to the normal counterpart (Figure 4b ). Patient's characteristics with respect to overexpression of miR-21 are shown in Table 1 . We divided patients in two groups using a cutoff value of 2.00, with samples having a 2 ÀDDCt value 42.00 considered highly expressing with respect to the others. As can be observed in Table 1 , patients with histology grade I/II tumors show high miR-21 expression in 21 of 30 (70%) cases and low expression in 9 of 30 (30%) cases, whereas patients with grade III/IV tumors show low mir-21 in 13 of 18 cases (72%) and high miR-21 in 5 of 18 (28%). Thus, there is a significantly different distribution of patients with high or low miR-21 overexpression between tumor stages (P ¼ 0.0016), with tumors highly expressing miR-21 being represented preferentially in early stages (I/II) and tumors with lower miR-21 expression mainly associated with later stages (III/IV). The other clinical parameters considered did not show significant association with miR-21 expression (Table 1) . miR-21 is strongly overexpressed in human anaplastic thyroid carcinomas Neoplastic transformation of thyroid epithelial cells can result in tumors of different histotypes. miR-21 overexpression seems not to be a characteristic of thyroid tumors as several published screenings of miRNAs in thyroid cancers did not report this miRNA in the list of the most expressed ones. We thus asked if human thyroid cancers overexpress mR-21 or if this happens only in in vitro transformed rat thyroid cells. We analyzed the expression of miR-21 in 20 samples of thyroid carcinomas, belonging to three different histotypes: papillary, follicular variant of papillary and anaplastic. Figure 5 shows that miR-21 expression is generally higher in cancer with respect to the normal thyroid tissue, and, importantly, that 7/10 anaplastic thyroid carcinomas express very high levels of such miRNA, demonstrating a marked overexpression of miR-21 specifically in the most aggressive subset of thyroid carcinomas. No association of miR-21 overexpression with the mutation status of Ras has been detected in this set of human tumors (Supplementary  Table S1 ).
miR-21 knockdown inhibits thyroid tumor growth in mouse
To test wether miR-21 overexpression has a role in the growth of thyroid tumor cells in vivo, we transfected constitutive Ras-transformed FRTL-5 cells (V27 clone) with a LNA oligonucleotide complementary to miR-21 (LNA-antimiR-21) or with a control LNA oligonucleotide (LNA-scrambled). miR-21 inhibition in V27 cells by LNA-antimiR-21 was confirmed by Q-RT-PCR (Figure 6a insert) . V27 cells transfected with LNAantimiR-21 or LNA-scrambled were injected subcutaneously in non-obese diabetic/severe combined immunodeficiency mice, and the tumor volumes were evaluated at different times after injection. As it is shown in Figure 6a , the growth of xenografted tumors was significantly inhibited at 15 and 25 days from injection when the V27 cells were transfected with LNAantimiR-21 with respect to the control cells transfected with the scrambled LNA. At 7, 14 and 21 days after injection, we checked miR-21 knockdown in xenografts, showing that between 7 and 14 days xenografted cells reexpress miR-21 (Figure 6b ). This may explain the lower signficance of the difference between the knockeddown and the control xenograft volumes at 25 days with respect to 15 days from injection (Po0.05 versus Po0.005, Figure 6a ).
miR-21 regulates genes involved in cell cycle regulatory networks
To identify cellular targets of miR-21 in thyroid we generated miR-21 overexpressing FRTL-5 cells. In order to overcome effects due to clonal variability, we selected five clones overexpressing miR-21 at different extents and pooled the corresponding total RNAs. Pooled total RNAs displayed 10-fold overexpression of miR-21 with respect to total RNA from parental FRTL-5 cells (data not shown). We then analyzed gene expression profiles in miR-21-overexpressing FRTL-5 compared with parental FRTL-5 cells, by microarrays analysis (see 
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Supplementary Methods). Differentially expressed genes were filtered for fold change 41.2, then for statistical significance (P-value 0.01) (Baek et al., 2008) resulting in 1861 differentially expressed genes (see Supplementary Methods). Of these, 1103 were downregulated and 758 upregulated. By using the Probability of Interaction by Target Accessibility (PITA) algorithm (Kertesz et al., 2007) , we identified predicted miR-21 targets in the list of differentially expressed genes, and calculated the distribution and cumulative distribution functions of the predicted targets and the nontarget probe sets (Grimson et al., 2007) (Figure 7a ). The two distributions belong to different populations with a P-value o1*10 À5 according to the two-sample Kolmogorov-Smirnov test, confirming that the overexpression of mir-21 downregulates preferentially its predicted targets, among which we found some of the known miR-21 targets (Btg2, Fam3c, Hipk3, Itgb1 and Pdcd4).
The whole set of 1861 DE probe sets, together with the subsets of 1103 downregulated and 758 upregulated ones, were categorized and filtered (P-value p1*10 À8 ) according to the gene ontology (GO) classification scheme, focusing on the GO biological process categories (see Supplementary Methods).
Several GO categories resulted enriched within the whole list of differentially expressed genes, however the GO terms enrichment resulted higher when the list of downregulated genes was used whereas the upregulated genes list did not produce any significant GO terms enrichment. In particular, we found 31 categories enriched in the downregulated list. Most of these categories were strictly related to cell cycle (Supplementary Table S2 ).
Functional characterization of downregulated genes was performed by using ingenuity pathway analysis, as described in Supplementary Methods. The list of downregulated genes was mapped to signaling networks in the ingenuity pathway analysis knowledge base. Among the eligible networks, the most significant is shown in Figure 7b . In the picture, dashed lines refer to indirect relations, full lines to direct ones (see also the legend inset). Black circled molecules of Figure 7b represent known miR-21 targets (Xiao et al., 2009) whereas double black circled ones are predicted targets present in downregulated genes list (see Supplementary  Methods) . The network has one major hub nodes, the tumor suppressor p53, which is downregulated in this experiment. The network building algorithm predicts that its regulatory signaling interaction network is significantly downregulated by the overexpression of miR-21. CKS2, a MIRANDA algorithm-predicted miR-21 target (John et al., 2004) , is known to regulate Cyclin B1 in human (Martinsson-Ahlzen et al., 2008) . Cyclin B1 is downregulated and contributes to the enrichment of the cell cycle GO category. Cyclin B1 is known to be expressed predominantly in the G2/M phase of cell division (Pines and Hunter, 1989) . Finally the hub UBE2 complex contains both downregulated genes and predicted mir-21 targets according to the PITA algorithm (John et al., 2004; Kertesz et al., 2007) .
The most enriched canonical pathway in this network resulted the cell cycle: G2/M DNA damage checkpoint regulation with a P-value o10 À4 . This pathway is shown in Figure 7c , where the downregulated genes are shaded. The 14-3-3 (b,e,z) complex contains YWAHB and YWHAZ, both downregulated, with YWAHB also Figure 7b and the pathway in Figure 7c share several genes: p53, Cyclin B1, TOP2A (a component of TopoII complex of the pathway), YWHAB and YWHAZ (components of 14-3-3 complex), p21 Cip1 and cdc25.
Discussion
This paper is concerned with the mechanisms leading to the elevation of miR-21 levels by oncogenic Ras and with the role of miR-21 in the onset and/or the progression of cancer. We have previously shown that oncogenic activation of Ras is able to elicit miR-21 expression in cultured thyroid cells and that AP-1 activity is necessary for such induction (Talotta et al., 2009) . We now show that induction of miR-21 by Ras occurs relatively early and it requires the activation of at least two Ras downstream pathways, the Raf-MAPK and the PI3K pathways. Elevation of miR-21 levels by Ras depends, in addition, on a proper cellular context as in fibroblasts miR-21 appears to be constitutively expressed and almost unresponsive to Ras oncogenic signaling, suggesting that cell-type specific mechanisms are involved in the regulation of such miRNA. Importantly, here we show that the ability of Ras in inducing miR-21 overexpression is not a phenomenon restricted to cultured cells, as it is observed in lung tumors induced by KRas oncogene in mice. This is the first evidence of a causal effect of Ras oncogenic activation on the induction of miR-21 in vivo. We analyzed miR-21 expression in human lung cancers and demonstrated that it is overexpressed in the majority of cases, accordingly to already reported data (Lu et al., 2005; Volinia et al., 2006; Yanaihara et al., 2006; Markou et al., 2008) . In our collection, however, we found significantly higher levels of miR-21 in early-stage tumors. This finding, together with the demonstration of miR-21 overexpression in experimental mouse lung cancers, suggests that miR-21 upregulation could be an early event in lung tumorigenesis, as it has also been suggested by a recent study showing that miR-21 is the most aberrantly increased miRNA also in lung tumors of never smokers (Seike et al., 2009) . Further studies will be necessary to establish if individual variations in miR-21 expression could be a risk factor for the development of lung cancer in humans. In this paper we show for the first time that miR-21 is strongly overexpressed specifically in anaplastic thyroid cancer. A previous screening of miRNA expression in anaplastic thyroid carcinomas did not reveal miR-21 overexpression (Visone et al., 2007) , however the apparent discrepancy with the data presented here could be because of the use of different experimental approaches. In fact, Visone et al. performed a genomewide miRNA expression profile by the use of a microarray platform, whereas we specifically measured miR-21 expression by using a TaqMan quantitative RT-PCR analysis.
We show here that the activation of both Raf/MAPK and PI3K pathways is necessary to achieve miR-21 overexpression in thyroid cells. Interestingly, these two pathways are often activated in combination specifically in anaplastic thyroid carcinomas (Liu et al., 2008; Miller et al., 2009) . This is also consistent with the previous observation of only a mild miR-21 overexpression in papillary thyroid cancers carrying activating mutations of Braf, which in turn specifically activate the MAPK pathway, while being unable to activate the PI3K pathway (He et al., 2005) .
To investigate a possible role of miR-21 overexpression in thyroid cancer we used a xenograft model of rat thyroid cells transformed by Ras injected subcutaneously in non-obese diabetic/severe combined immunodeficiency mice. In such system, knockdown of miR-21 was able to strongly inhibit the growth of tumor xenografts. Interestingly, we previously carried out similar miR-21 knockdown experiments in vitro, showing only mild negative effects on proliferation (Talotta et al., 2009) , thus suggesting that the proliferative advantage conferred by miR-21 to tumor cells is particularly important to allow the tumor growth in vivo.
Moreover, by using miR-21-overexpressing cells, we investigated at the whole genome level the effects of miR-21 on the transcriptome. Genes regulated by miR-21 in thyroid cells are enriched in categories involved in cell cycle and DNA damage response, especially by looking selectively at downregulated genes. It has been reported that oncogenic Ras is able to induce chromosome instability and to accelerate G2/M transition (Abulaiti et al., 2006; Knauf et al., 2006) , thus we hypotesize that miR-21 could contribute to the ability of Ras-transformed cells to overcome the G2 DNA damage checkpoint successfully. We plan to perform additional experiments to verify this hypothesis.
An intriguing finding of this paper is the opposite correlation of miR-21 overexpression with tumor progression in lung with respect to thyroid. It is possible to hypotesize that the characteristics conferred by miR-21 overexpression promote the progression of thyroid tumors towards more advanced stages. This is supported by the identification of networks targeted in thyroid reported here, showing that miR-21 in these cells could contribute to genomic instability, typical of advanced cancers. Conversely, miR-21 overexpression in lung could be advantageous preferentially in the early stages of tumor progression, as suggested by data indicating that in this cell type miR-21 is mainly involved in protection from apoptosis (Seike et al., 2009) , which, in turn, is mainly critical in early stages of tumor development.
In conclusion, the data presented here add new informations about the Ras effectors required for the induction of miR-21 expression and establish for the first time a link in vivo between the Ras oncogene, whose activation is involved in about one-third of human cancers, and the overexpression of miR-21. Our future plans include the generation of a miR-21 knockout mouse, to demonstrate the role played in vivo by miR-21 in neoplastic transformation of several cell types, but
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